[A14-31] Daclatasvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Last updated 01.12.2014
Project no.:
A14-31
Commission:
Commission awarded on 02.09.2014 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2015-03-19 A G-BA decision was published.